Understanding Epilepsies with In Vitro Disease Models

4-AP model SCN1A model Developmental model

Epilepsy, a prevalent neurological disorder, manifests as recurrent unprovoked seizures across various syndromes. Despite advancements in antiepileptic drugs, a significant proportion of patients remain unresponsive to current treatments, highlighting the need for novel therapeutic avenues.

At NeuroProof, we address this challenge with cutting-edge in vitro screening assays designed to probe the mechanisms of epileptogenesis and evaluate the efficacy of emerging antiepileptic compounds. Our assays offer a deeper understanding of the epileptic condition and aid in the development of targeted therapies.

Our Approach:

  • Diverse Assay Models: We have developed specialized in vitro models tailored with our MEA approach and sophisticated data analysis to investigate different aspects of epilepsy, including:
    • 4-AP Model: Mimics epileptiform activity induced by 4-aminopyridine, aiding in the study of seizure mechanisms.
    • SCN1A Model: Focuses on mutations in the SCN1A gene associated with Dravet syndrome, a severe form of epilepsy.
    • Developmental Model: Explores the impact of developmental factors on epileptogenesis, offering insights into early intervention strategies.

  • Human iPSC-Derived Neurons: Our assays leverage human induced pluripotent stem cell (iPSC) technology, enhancing translational relevance and facilitating drug discovery in a human-specific context.
  • Comprehensive Analysis: Utilizing advanced classification algorithms, we assess the excitatory or pro-convulsive potential of test compounds. Our side-effect assays provide valuable insights into compound safety profiles.
  • Probing Pro-Convulsive Mechanisms: Our technology enables the investigation of pro-convulsive compounds such as picrotoxin, shedding light on their effects on network activity and ictal-like discharges in frontal cortex cultures.

Why Choose NeuroProof:

  • Expertise: Our team comprises experts in neuroscience, pharmacology, and assay development, dedicated to advancing epilepsy research and drug discovery.
  • Innovation: We continuously refine our assays and technologies to stay at the forefront of epilepsy research, offering state-of-the-art solutions to our clients.
  • Collaboration: We welcome collaborations with research institutions, pharmaceutical companies, and biotech firms to accelerate the development of novel therapies for epilepsy.

Contact Us:

For further information on our epilepsy assays and how they can drive your research forward.

Contact us for further information!